Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online March 28, 2023.
Article Versions
- Latest version (February 15, 2023 - 04:00).
- Latest version (March 1, 2023 - 04:00).
- You are currently viewing a Latest version of this article (March 28, 2023 - 10:05).
- View the most recent version of this article
Copyright & Usage
© 2023 The Journal of Rheumatology
Author Information
- Atul Deodhar,
- Denis Poddubnyy,
- Proton Rahman,
- Jeorg Ermann,
- Tetsuya Tomita,
- Rebeca Bolce,
- Soyi Liu Leage,
- Andris Kronbergs,
- Caroline Johnson,
- Joana Araújo,
- Ann Leung and
- Désirée van der Heijde
- A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA.
- D. Poddubnyy, MD, Rheumatology Department, Charité - Universitätsmedizin Berlin, Berlin, Germany. and German Rheumatism Research Centre, Berlin, Germany.
- P. Rahman, MD, Department of Medicine, Memorial University of Newfoundland, Newfoundland and Labrador, Canada.
- J. Ermann, MD, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- T. Tomita, MD, Department of Orthopedic Surgery, Osaka University Hospital, Osaka, Japan.
- R. Bolce, MSN, S. Liu Leage, MD, A. Kronbergs, PhD, C. Johnson, MD, J. Araújo, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA.
- R. Bolce, MSN, S. Liu Leage, MD, A. Kronbergs, PhD, C. Johnson, MD, J. Araújo, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA.
- R. Bolce, MSN, S. Liu Leage, MD, A. Kronbergs, PhD, C. Johnson, MD, J. Araújo, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA.
- R. Bolce, MSN, S. Liu Leage, MD, A. Kronbergs, PhD, C. Johnson, MD, J. Araújo, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA.
- A. Leung, MS, Syneos Health Inc., Morrisville, North Carolina, USA.
- D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
-
This study was funded by Eli Lilly and Company (Indianapolis, Indiana, USA).
AD reports consulting and advisory boards for AbbVie, Amgen, Aurinia, Boehringer Ingelheim, BMS, Celgene, Eli Lilly and Company, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB; and research grants from AbbVie, Eli Lilly and Company, GSK, Novartis, Pfizer, and UCB. DP reports research grants from AbbVie, Eli Lilly and Company, MSD, Novartis, and Pfizer; consulting fees from AbbVie, Biocad, Eli Lilly and Company, Galapagos, Gilead, GSK, Janssen, MSD, Moonlake, Novartis, Pfizer, Samsung Bioepis, and UCB; transportation and travel fees from Eli Lilly and Company; and personal speaker fees from AbbVie, BMS, Eli Lilly and Company, Janssen, MSD, Medscape, Novartis, Peervoice, Pfizer, and UCB. PR has received consulting fees and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, travel, or educational events from AbbVie, Amgen, Celgene, Pfizer, Janssen, Novartis, and Eli Lilly and Company. JE has received research support from AbbVie, Novartis, and Pfizer; payment for transport/travel from Eli Lilly and Company; and consulting fees from Eli Lilly and Company, Novartis, Pfizer, and UCB. TT serves as a principal investigator of spondyloarthritis grants by the Ministry of Health, Labour, and Welfare of Japan. RB, SLL, AK, CJ, and JA are employees and shareholders of Eli Lilly and Company. AL is an employee of Syneos Health and a vendor of Eli Lilly and Company. DvdH reports consulting fees from AbbVie, Bayer, BMS, Cyxone, Eisai, Eli Lilly and Company, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB; personal speaker fees from Eli Lilly and Company; and serves as Director of Imaging Rheumatology BV.
Accepted for publication February 6, 2023.
- Address correspondence to Dr. A. Deodhar, Division of Arthritis & Rheumatic Diseases, 3181 SW Sam Jackson Park Rd, Oregon Health & Science University, Portland, OR 97239, USA. Email: deodhara@ohsu.edu.